Table 2.
Baseline demographics and disease characteristics
| IVT-AFL 2 mg n = 27 |
Sham/IVT-AFL n = 27 |
Total n = 54 |
|
|---|---|---|---|
| Male, n (%) | 22 (82) | 23 (85) | 45 (83) |
| Mean age, years (SD) | 68.1 (13) | 66.2 (14) | 67.1 (13) |
| Primary diagnosis, n (%) | |||
| Proliferative diabetic retinopathy | 10 (37) | 13 (48) | 23 (43) |
| Central retinal vein occlusion | 11 (41) | 5 (19) | 16 (30) |
| Ocular ischemic syndrome | 4 (15) | 5 (19) | 9 (17) |
| Other | 2 (7) | 4 (15) | 6 (11) |
| Duration of disease, ≤ 6.0 days, n (%) | 17 (63) | 10 (37) | 27 (50) |
| Stage of NVG, n (%) | |||
| Open angle | 24 (89) | 23 (85) | 47 (87) |
| Closed angle | 3 (11) | 4 (15) | 7 (13) |
| NVI grade 3 or 4 at baseline (pooled), n (%) | 13 (48) | 7 (26) | 20 (37) |
| NVA grade 3 or 4 at baseline (pooled), n (%) | 19 (70) | 15 (56) | 34 (63) |
| Mean IOP at baseline, mmHg (SD) | 33 (10) | 37 (9) | 35 (10) |
IOP intraocular pressure, IVT-AFL intravitreal aflibercept, NVA neovascularization of the angle, NVG neovascular glaucoma, NVI neovascularization of the iris, SD standard deviation